106 related articles for article (PubMed ID: 38783575)
1. Accurate and comprehensive evaluation of O6-methylguanine-DNA methyltransferase promoter methylation by nanopore sequencing.
Halldorsson S; Nagymihaly RM; Patel A; Brandal P; Panagopoulos I; Leske H; Lund-Iversen M; Sahm F; Vik-Mo EO
Neuropathol Appl Neurobiol; 2024 Jun; 50(3):e12984. PubMed ID: 38783575
[TBL] [Abstract][Full Text] [Related]
2. MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status.
Bady P; Sciuscio D; Diserens AC; Bloch J; van den Bent MJ; Marosi C; Dietrich PY; Weller M; Mariani L; Heppner FL; Mcdonald DR; Lacombe D; Stupp R; Delorenzi M; Hegi ME
Acta Neuropathol; 2012 Oct; 124(4):547-60. PubMed ID: 22810491
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of test(s) for O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation for predicting overall survival in people with glioblastoma treated with temozolomide.
McAleenan A; Kelly C; Spiga F; Kernohan A; Cheng HY; Dawson S; Schmidt L; Robinson T; Brandner S; Faulkner CL; Wragg C; Jefferies S; Howell A; Vale L; Higgins JPT; Kurian KM
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD013316. PubMed ID: 33710615
[TBL] [Abstract][Full Text] [Related]
4. MGMT promoter methylation in patients with glioblastoma: is methylation-sensitive high-resolution melting superior to methylation-sensitive polymerase chain reaction assay?
Yamashita S; Yokogami K; Matsumoto F; Saito K; Mizuguchi A; Ohta H; Takeshima H
J Neurosurg; 2018 May; 130(3):780-788. PubMed ID: 29726772
[TBL] [Abstract][Full Text] [Related]
5. The number of methylated CpG sites within the MGMT promoter region linearly correlates with outcome in glioblastoma receiving alkylating agents.
Siller S; Lauseker M; Karschnia P; Niyazi M; Eigenbrod S; Giese A; Tonn JC
Acta Neuropathol Commun; 2021 Mar; 9(1):35. PubMed ID: 33663593
[TBL] [Abstract][Full Text] [Related]
6. Detection of MGMT promoter methylation in glioblastoma using pyrosequencing.
Xie H; Tubbs R; Yang B
Int J Clin Exp Pathol; 2015; 8(2):1790-6. PubMed ID: 25973069
[TBL] [Abstract][Full Text] [Related]
7. Assessment of MGMT methylation status using high-performance liquid chromatography in newly diagnosed glioblastoma.
Hanihara M; Miyake K; Watanabe A; Yamada Y; Oishi N; Kawataki T; Inukai T; Kondo T; Kinouchi H
Clin Epigenetics; 2020 Nov; 12(1):174. PubMed ID: 33203454
[TBL] [Abstract][Full Text] [Related]
8. A distinct region of the MGMT CpG island critical for transcriptional regulation is preferentially methylated in glioblastoma cells and xenografts.
Malley DS; Hamoudi RA; Kocialkowski S; Pearson DM; Collins VP; Ichimura K
Acta Neuropathol; 2011 May; 121(5):651-61. PubMed ID: 21287394
[TBL] [Abstract][Full Text] [Related]
9. Defining optimal cutoff value of MGMT promoter methylation by ROC analysis for clinical setting in glioblastoma patients.
Yuan G; Niu L; Zhang Y; Wang X; Ma K; Yin H; Dai J; Zhou W; Pan Y
J Neurooncol; 2017 May; 133(1):193-201. PubMed ID: 28516344
[TBL] [Abstract][Full Text] [Related]
10. Impact on prognosis of the regional distribution of MGMT methylation with respect to the CpG island methylator phenotype and age in glioma patients.
Mur P; Rodríguez de Lope Á; Díaz-Crespo FJ; Hernández-Iglesias T; Ribalta T; Fiaño C; García JF; Rey JA; Mollejo M; Meléndez B
J Neurooncol; 2015 May; 122(3):441-50. PubMed ID: 25682093
[TBL] [Abstract][Full Text] [Related]
11. Prognostic prediction of glioblastoma by quantitative assessment of the methylation status of the entire MGMT promoter region.
Kanemoto M; Shirahata M; Nakauma A; Nakanishi K; Taniguchi K; Kukita Y; Arakawa Y; Miyamoto S; Kato K
BMC Cancer; 2014 Aug; 14():641. PubMed ID: 25175833
[TBL] [Abstract][Full Text] [Related]
12. Detection of MGMT promoter methylation in glioblastoma using pyrosequencing.
Xie H; Tubbs R; Yang B
Int J Clin Exp Pathol; 2015; 8(1):636-42. PubMed ID: 25755756
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of MGMT promoter methylation status and correlation with temozolomide response in orthotopic glioblastoma xenograft model.
Kitange GJ; Carlson BL; Mladek AC; Decker PA; Schroeder MA; Wu W; Grogan PT; Giannini C; Ballman KV; Buckner JC; James CD; Sarkaria JN
J Neurooncol; 2009 Mar; 92(1):23-31. PubMed ID: 19011762
[TBL] [Abstract][Full Text] [Related]
14. Clinically Relevant Imaging Features for
Suh CH; Kim HS; Jung SC; Choi CG; Kim SJ
AJNR Am J Neuroradiol; 2018 Aug; 39(8):1439-1445. PubMed ID: 30002055
[TBL] [Abstract][Full Text] [Related]
15. Variation of O(6)-methylguanine-DNA methyltransferase (MGMT) promoter methylation in serial samples in glioblastoma.
Parkinson JF; Wheeler HR; Clarkson A; McKenzie CA; Biggs MT; Little NS; Cook RJ; Messina M; Robinson BG; McDonald KL
J Neurooncol; 2008 Mar; 87(1):71-8. PubMed ID: 18004504
[TBL] [Abstract][Full Text] [Related]
16. Assessing CpG island methylator phenotype, 1p/19q codeletion, and MGMT promoter methylation from epigenome-wide data in the biomarker cohort of the NOA-04 trial.
Wiestler B; Capper D; Hovestadt V; Sill M; Jones DT; Hartmann C; Felsberg J; Platten M; Feiden W; Keyvani K; Pfister SM; Wiestler OD; Meyermann R; Reifenberger G; Pietsch T; von Deimling A; Weller M; Wick W
Neuro Oncol; 2014 Dec; 16(12):1630-8. PubMed ID: 25028501
[TBL] [Abstract][Full Text] [Related]
17. Correlation of MGMT promoter methylation status with gene and protein expression levels in glioblastoma.
Uno M; Oba-Shinjo SM; Camargo AA; Moura RP; Aguiar PH; Cabrera HN; Begnami M; Rosemberg S; Teixeira MJ; Marie SK
Clinics (Sao Paulo); 2011; 66(10):1747-55. PubMed ID: 22012047
[TBL] [Abstract][Full Text] [Related]
18. Clinical correlation of MGMT protein expression and promoter methylation in Chinese glioblastoma patients.
Tang K; Jin Q; Yan W; Zhang W; You G; Liu Y; Jiang T
Med Oncol; 2012 Jun; 29(2):1292-6. PubMed ID: 21394635
[TBL] [Abstract][Full Text] [Related]
19. Combined analysis of O6-methylguanine-DNA methyltransferase protein expression and promoter methylation provides optimized prognostication of glioblastoma outcome.
Lalezari S; Chou AP; Tran A; Solis OE; Khanlou N; Chen W; Li S; Carrillo JA; Chowdhury R; Selfridge J; Sanchez DE; Wilson RW; Zurayk M; Lalezari J; Lou JJ; Ormiston L; Ancheta K; Hanna R; Miller P; Piccioni D; Ellingson BM; Buchanan C; Mischel PS; Nghiemphu PL; Green R; Wang HJ; Pope WB; Liau LM; Elashoff RM; Cloughesy TF; Yong WH; Lai A
Neuro Oncol; 2013 Mar; 15(3):370-81. PubMed ID: 23328811
[TBL] [Abstract][Full Text] [Related]
20. Identification of regions correlating MGMT promoter methylation and gene expression in glioblastomas.
Everhard S; Tost J; El Abdalaoui H; Crinière E; Busato F; Marie Y; Gut IG; Sanson M; Mokhtari K; Laigle-Donadey F; Hoang-Xuan K; Delattre JY; Thillet J
Neuro Oncol; 2009 Aug; 11(4):348-56. PubMed ID: 19224763
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
